XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million

Reuters

2025/11/12

XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million

XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582376301"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582376301\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582376301?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582376301","market":"nz","top_or_hot":-1,"title":"XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of <a href=\"https://laohu8.com/S/TSBX\">Turnstone Biologics</a> and HilleVax, announced acquisitions of LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a>, and acted as structuring agent for XenoTherapeutics' acquisition of <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma</a>. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-12 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of <a href=\"https://laohu8.com/S/TSBX\">Turnstone Biologics</a> and HilleVax, announced acquisitions of LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a>, and acted as structuring agent for XenoTherapeutics' acquisition of <a href=\"https://laohu8.com/S/EPIX\">ESSA Pharma</a>. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5JJSXp:1","article_id":"2582376301","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582376301","pubTimestamp":1762950640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4539":"次新股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","HLVX":"HilleVax, Inc.","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","XOMA":"标记临床研究","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LVTX":"LAVA Therapeutics N.V.","EPIX":"ESSA Pharma Inc."},"translate_title":"XOMA Royalty报告第三季度收入为940万美元，年初至今收入为3840万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"LVTX":0.9,"HLVX":0.9,"XOMA":0.9,"EPIX":0.9},"content_text":"XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million\n    \n\n        XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma. The company also secured royalty economic interests in partnered assets through the planned acquisition of LAVA Therapeutics.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573768-en) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}